Cargando…
Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer
Circular RNA (circRNA) is considered to be an important regulator that mediates cancer chemoresistance. But whether circ-LPAR3 is involved in ovarian cancer (OC) cisplatin (DDP) resistance is unclear. The circ-LPAR3, miR-634 and pyruvate dehydrogenase kinase 1 (PDK1) expression was measured by quant...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974081/ https://www.ncbi.nlm.nih.gov/pubmed/35081867 http://dx.doi.org/10.1080/21655979.2022.2029109 |
_version_ | 1784680185227902976 |
---|---|
author | Liu, Xuemei Yin, Zhiping Wu, Yanjun Zhan, Qian Huang, Honghong Fan, Jiangtao |
author_facet | Liu, Xuemei Yin, Zhiping Wu, Yanjun Zhan, Qian Huang, Honghong Fan, Jiangtao |
author_sort | Liu, Xuemei |
collection | PubMed |
description | Circular RNA (circRNA) is considered to be an important regulator that mediates cancer chemoresistance. But whether circ-LPAR3 is involved in ovarian cancer (OC) cisplatin (DDP) resistance is unclear. The circ-LPAR3, miR-634 and pyruvate dehydrogenase kinase 1 (PDK1) expression was measured by quantitative real-time PCR (qRT-PCR). Cell cisplatin resistance and viability were measured by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) assay. In addition, cell colony number, apoptosis, and metastasis were assessed by colony formation assay, flow cytometry and transwell assay. Furthermore, in vivo experiments were performed by constructing mice xenograft models. RNA interaction was confirmed by dual-luciferase reporter assay, and PDK1 protein expression was examined by Western blot analysis. Our results showed that circ-LPAR3 was markedly upregulated in DDP-resistant OC tissues and cells. Silencing of circ-LPAR3 enhanced the DDP sensitivity of OC cells and tumors. MiR-634 could interact with circ-LPAR3, and its inhibitor overturned the regulation of si-circ-LPAR3 on cell DDP resistance. Additionally, PDK1 was targeted by miR-634, and its overexpression inverted the effect of miR-634 on cell DDP resistance. To sum up, circ-LPAR3 might contribute to the DDP resistance of OC via the miR-634/PDK1 axis. |
format | Online Article Text |
id | pubmed-8974081 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-89740812022-04-02 Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer Liu, Xuemei Yin, Zhiping Wu, Yanjun Zhan, Qian Huang, Honghong Fan, Jiangtao Bioengineered Research Paper Circular RNA (circRNA) is considered to be an important regulator that mediates cancer chemoresistance. But whether circ-LPAR3 is involved in ovarian cancer (OC) cisplatin (DDP) resistance is unclear. The circ-LPAR3, miR-634 and pyruvate dehydrogenase kinase 1 (PDK1) expression was measured by quantitative real-time PCR (qRT-PCR). Cell cisplatin resistance and viability were measured by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) assay. In addition, cell colony number, apoptosis, and metastasis were assessed by colony formation assay, flow cytometry and transwell assay. Furthermore, in vivo experiments were performed by constructing mice xenograft models. RNA interaction was confirmed by dual-luciferase reporter assay, and PDK1 protein expression was examined by Western blot analysis. Our results showed that circ-LPAR3 was markedly upregulated in DDP-resistant OC tissues and cells. Silencing of circ-LPAR3 enhanced the DDP sensitivity of OC cells and tumors. MiR-634 could interact with circ-LPAR3, and its inhibitor overturned the regulation of si-circ-LPAR3 on cell DDP resistance. Additionally, PDK1 was targeted by miR-634, and its overexpression inverted the effect of miR-634 on cell DDP resistance. To sum up, circ-LPAR3 might contribute to the DDP resistance of OC via the miR-634/PDK1 axis. Taylor & Francis 2022-01-26 /pmc/articles/PMC8974081/ /pubmed/35081867 http://dx.doi.org/10.1080/21655979.2022.2029109 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Paper Liu, Xuemei Yin, Zhiping Wu, Yanjun Zhan, Qian Huang, Honghong Fan, Jiangtao Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer |
title | Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer |
title_full | Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer |
title_fullStr | Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer |
title_full_unstemmed | Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer |
title_short | Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer |
title_sort | circular rna lysophosphatidic acid receptor 3 (circ-lpar3) enhances the cisplatin resistance of ovarian cancer |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974081/ https://www.ncbi.nlm.nih.gov/pubmed/35081867 http://dx.doi.org/10.1080/21655979.2022.2029109 |
work_keys_str_mv | AT liuxuemei circularrnalysophosphatidicacidreceptor3circlpar3enhancesthecisplatinresistanceofovariancancer AT yinzhiping circularrnalysophosphatidicacidreceptor3circlpar3enhancesthecisplatinresistanceofovariancancer AT wuyanjun circularrnalysophosphatidicacidreceptor3circlpar3enhancesthecisplatinresistanceofovariancancer AT zhanqian circularrnalysophosphatidicacidreceptor3circlpar3enhancesthecisplatinresistanceofovariancancer AT huanghonghong circularrnalysophosphatidicacidreceptor3circlpar3enhancesthecisplatinresistanceofovariancancer AT fanjiangtao circularrnalysophosphatidicacidreceptor3circlpar3enhancesthecisplatinresistanceofovariancancer |